---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026913"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:15:42.629514+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics (CADL) appoints Nicoletta Loggia, PhD, RPh to board effective June 7, 2023

## Summary
- Board size increased from 9 to 10; Dr. Loggia appointed as Class III director with term expiring at 2024 annual meeting.
- She receives option for 28,480 shares vesting over 3 years plus standard non-employee director cash compensation.
- Dr. Loggia is CTO at Orchard Therapeutics, formerly Global Head of Cell & Gene Therapies at Novartis, with 20+ years experience.
- Appointment adds manufacturing expertise as company approaches phase 3 pivotal readout in localized prostate cancer.

## SEC filing metadata
- accession: 0000950170-23-026913
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023026913/0000950170-23-026913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023026913/cadl-20230605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026913
- JSON: https://secwatch.observer/filing/0000950170-23-026913.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026913.txt

## Key facts
- Executive change
  Nicoletta Loggia was appointed as Class III Director at Candel Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: unanimously appointed Nicoletta Loggia, Ph.D., R.Ph., to fill the newly created vacancy on the Board, effective June 7, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017023026913/0000950170-23-026913-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.